Search for content, post, videos

Diaprost enters license agreement

Johan Drott

Diaprost licenses its novel Theranostic Antibody, hu5A10, to Radiopharm Theranostics for development in the treatment and diagnosis of prostate cancer.

Radiopharm Theranostics (RAD) is an Australian based biotech startup, focused on building a pipeline of radiopharmaceutical products for both diagnostic and therapeutic uses. RAD has recently raised A$20 million to progress a portfolio of radiopharmaceutical assets that have the potential to be first to market or best in class in their respective disease areas. The Diaprost asset is one of four distinct & clearly differentiated platform technologies.

Upfront and near-term payments of 10 million USD

Under the terms of the agreement RAD will have exclusive responsibility to manufacture, develop and commercialise Diaprost’s hu5A10 worldwide. Upfront and near-term payments of US$10M are part of a financial package that over the life of the agreement could exceed US$125M, if all development and regulatory goals are met.

“We believe the Licensing Agreement with Radiopharm Theranostics, founded by the experienced Australian life sciences industry figure Paul Hopper, represents a focused route to maximizing the potential of both Diaprost and the hu5A10 program,” says Johan Drott, the CEO of Diaprost. “RAD has established a strong management team with recognised experts to focus on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.”

The Diaprost pipeline

The Diaprost pipeline is focused on humanised antibodies for diagnostic and therapeutic radiopharmaceutical applications. The hu5A10 antibody enables non-invasive detection and therapy by delivering radionuclides to prostate cancer cells. The platform’s targeting mechanism utilizes binding to Prostate Specific Antigen (PSA), a well-established biomarker previously only applied for diagnostic blood tests.

The imaging modalities based on hu5A10, which were developed together with Lasker Award recipient Charles Sawyers, demonstrate superior specificities in diagnosing prostate cancer cell occurrence and an unparalleled ability to detect disease activity, states the company. When employing hu5A10 with a Therapeutic Isotope, results demonstrate specific and effective prostate cancer cell eradication. The combination of imaging and radioimmunotherapy, based on the same antibody, enables a powerful tool for both diagnosis and treatment of prostate cancer.

Photo of Johan Drott: Diaprost